Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 1 | BMC Molecular and Cell Biology

Fig. 1

From: Structural insights into the non-inhibitory mechanism of the anti-EGFR EgB4 nanobody

Fig. 1

The CDR3 of EgB4 is substantially shorter than that of other anti-EGFR nanobodies. (Left) Structural alignment of four described anti-EGFR nanobodies showing the difference in CDR3 length. Inset shows the complete EgB4 nanobody. FR: framework region (grey). (Right) Corresponding sequence alignment with residues numbered according to the EgB4 sequence. A sequence alignment following the ImMunoGeneTics (IMGT) numbering is shown in Fig. S2

Back to article page

BMC Molecular and Cell Biology

ISSN: 2661-8850

Contact us